What Is Cagrilintide?

Cagrilintide is a long-acting amylin analog peptide that researchers are studying for weight loss and blood sugar control. It mimics amylin, a hormone the pancreas releases alongside insulin after a meal to create fullness and slow digestion. Cagrilintide is not FDA-approved for human use in the United States, and it is available only to people enrolled in clinical trials.

Cagrilintide at a Glance

Cagrilintide belongs to the amylin family of metabolic peptides rather than the GLP-1 family. The table below covers the basics that come up most often when people ask what is cagrilintide peptide and how it is used in research.

Attribute	Details
Peptide class	Long-acting amylin analog
Hormone mimicked	Amylin (islet amyloid polypeptide)
Primary receptor target	Amylin receptors in the hindbrain
Dosing studied	Once-weekly subcutaneous injection
Research focus	Obesity, type 2 diabetes, combination therapy
Common pairing	Semaglutide (combination known as CagriSema)
Regulatory status	Investigational; not FDA-approved

How Does Cagrilintide Work?

Amylin is released by the same pancreatic cells that produce insulin. It travels to the hindbrain, activates amylin receptors, and signals that food has arrived.

That signal produces three main effects: it increases satiety, slows the rate at which the stomach empties, and reduces post-meal glucose release from the liver. Cagrilintide reproduces each of those effects.

Cagrilintide carries a fatty-acid side chain that binds to albumin in the bloodstream. That change slows the molecule's breakdown and supports once-weekly dosing, which is the heart of the cagrilintide mechanism of action.

The short answer to what does cagrilintide do is simple: it turns up the body's natural fullness signal and keeps it elevated far longer than amylin alone.

Cagrilintide vs. GLP-1 Peptides

Cagrilintide is frequently grouped with GLP-1 drugs, but it is not a GLP-1 receptor agonist. It works through amylin receptors, so the two classes act on separate pathways and can be combined.

Feature	Cagrilintide	Semaglutide
Peptide class	Amylin analog	GLP-1 receptor agonist
Hormone mimicked	Amylin	GLP-1
Primary target	Amylin receptors	GLP-1 receptor
Half-life support	Albumin binding	Albumin binding
Main studied effects	Fullness, slower gastric emptying	Appetite, insulin release, gastric emptying
FDA status	Investigational	Approved for diabetes and obesity

Semaglutide, sold as Ozempic and Wegovy, is the most common comparison point. CagriSema pairs cagrilintide with semaglutide in a single weekly injection, and that combination is what most late-stage trials are testing.

What Is Cagrilintide Used For in Research?

Most cagrilintide research falls into a few categories:

• Obesity treatment: reducing body weight in adults with obesity or overweight plus a related condition.
• Type 2 diabetes: improving blood sugar control, sometimes alongside insulin.
• Combination therapy: testing amylin plus GLP-1 activity in one regimen.
• Tolerability studies: comparing side effect profiles and dose escalation schedules.

Novo Nordisk's REDEFINE phase 3 program reported roughly 20% average weight loss at 68 weeks when cagrilintide was combined with semaglutide in adults with obesity. Cagrilintide has not been shown to cure obesity or diabetes, and no regulator has approved it for any indication.

Is Cagrilintide a Peptide, and Is It FDA-Approved?

Yes, cagrilintide is a peptide. It is a synthetic version of human amylin with amino acid substitutions and a fatty-acid side chain that keep it stable in the body far longer than the natural hormone.

Because it is a peptide, it cannot survive digestion and must be given by subcutaneous injection. No oral form of cagrilintide exists.

Cagrilintide is not approved by the FDA or by any other regulatory agency. Vials sold online as a "cagrilintide research peptide" are marketed for laboratory use, are not manufactured to pharmaceutical standards, and are not intended for human consumption.

Safety, Handling, and Related Research Peptides

Reported side effects

In published trials, the most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. They are usually mild to moderate and most frequent during dose increases.

Because cagrilintide slows stomach emptying and suppresses appetite, people may eat noticeably less. When it is used with insulin or sulfonylureas, low blood sugar becomes a real risk that requires medical supervision.

Anyone considering an investigational peptide should speak with a licensed healthcare professional before using it. Self-dosing with unapproved research chemicals carries risks that clinical trials are specifically designed to monitor.

Handling in a laboratory setting

Cagrilintide is typically shipped as a lyophilized powder and stored frozen or refrigerated until use. Before an assay, it is dissolved in a suitable diluent according to the study protocol.

People who look up what is bacteriostatic water for injection used for are usually trying to understand that dissolving step. Bacteriostatic water contains 0.9% benzyl alcohol, which limits bacterial growth, but it is not appropriate for every peptide or every laboratory method.

How it compares with other peptides

Cagrilintide sits in the metabolic peptide category, alongside amylin and GLP-1 research. It is not a tissue-repair compound, so questions such as what is bpc 157 peptide or what is igf-1 lr3 used for point to entirely different areas of study.

Search interest in what is kpv peptide used for reflects another separate field focused on a small anti-inflammatory peptide. Cagrilintide shares the "peptide" label with those compounds but almost nothing else.

COMMON QUESTIONS

Frequently Asked Questions

What is cagrilintide used for?

Cagrilintide is being studied for obesity and type 2 diabetes, most often in combination with the GLP-1 drug semaglutide. In trials it is given as a once-weekly injection to increase fullness and slow stomach emptying. It is not approved for any use outside of clinical research.

Is cagrilintide FDA-approved?

No. Cagrilintide is an investigational drug and has not been approved by the FDA for human use in the United States. It is available only to participants enrolled in clinical trials. Products sold online as research-grade cagrilintide are not approved medicines.

Is cagrilintide a peptide or a GLP-1?

Cagrilintide is a peptide, and more specifically it is an amylin analog, not a GLP-1 receptor agonist. It activates amylin receptors in the brain rather than GLP-1 receptors. That difference is why researchers combine it with semaglutide instead of using it as a replacement.